盐酸埃克替尼治疗肺腺癌进展后加量治疗的疗效及安全性分析  

Clinical efficacy and safety analysis of additional dose of icotinib in treatment of advanced lung adenocarcinoma

作　　者：郑清月 闫春良[1] 赵秋红[1] Zheng Qingyue;Yan Chunliang;Zhao Qiuhong(Department of Respiratory Medicine,Beijing Aerospace General Hospital,Beijing 100076,China)

机构地区：[1]北京航天总医院呼吸内科,北京100076

出　　处：《实用肿瘤杂志》2020年第3期231-235,共5页Journal of Practical Oncology

摘　　要：目的评价盐酸埃克替尼一线常规剂量治疗肺腺癌进展后盐酸埃克替尼加量治疗的疗效及安全性。方法收集22例ⅢB或IV期肺腺癌患者,经一线埃克替尼常规剂量(125 mg口服3次/d)治疗耐药后,给予盐酸埃克替尼加量治疗(150~450 mg口服3次/d),进行回顾性分析,评估埃克替尼加量疗效及安全性。结果22例晚期肺腺癌患者中,完全缓解0例(0%),部分缓解7例(31.8%),疾病稳定9例(40.9%),疾病进展6例(27.3%),客观缓解率为31.8%,疾病控制率为72.7%,中位无进展生存期为6个月(95%CI:3.702~8.298个月),中位总生存期为11个月(95%CI:7.260~14.740个月)。埃克替尼加量治疗常见的不良反应为皮疹、食欲下降及腹泻,均为1~2级。结论对于一线盐酸埃克替尼常规剂量治疗耐药的晚期肺腺癌患者,盐酸埃克替尼加量治疗可作为二线选择方案。盐酸埃克替尼加量治疗安全性较高。Objective To investigate the efficacy and safety of additional dose of icotinib in patients with lung adenocarcinoma after failure of recommended dose of icotinib treatment.Methods This study comprised 22 stage ⅢB or Ⅳ lung adenocarcinoma patients.Initially,patients received oral icotinib(125 mg,tid)alone.When the disease progressed,they received additional dose of icotinib(150-450 mg,tid)alone.The efficacy and safety of additional dose of icotinib in the 22 patients were analyzed.Results Among the 22 patients with advanced lung adenocarcinoma,no patient had complete response,7(31.8%)had partial response,9(40.9%)had stable disease,and 6(27.3%)had progressive disease.The objective response rate(ORR)was 31.8%,and disease control rate(DCR)was 72.7%.The median progression-free survival was 6 months(95%CI:3.702-8.298 months),and the median overall survival was 11 months(95%CI:7.260-14.740 months).The most common adverse reactions of additional dose of icotinib were skin rashes,loss of appetite,and diarrhea,which were all grade 1 or 2.Conclusions For advanced lung adenocarcinoma patients who has failed in the routine first-line therapy of icotinib,the additional dose of icotinib can be used as a second-line option.The additional dose of icotinib is safe in treatment.

关 键 词：肺肿瘤/药物疗法 腺癌/药物疗法 喹唑啉类/治疗应用 喹唑啉类/投药和剂量 冠醚类/治疗应用 冠醚类/投药和剂量 治疗结果 安全 回顾性研究 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]